In December, the U.S. Food and Drug Administration (FDA) approved crinecerfont capsules and oral solution adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH). Crinecerfont is a selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist that directly […]
New CAH Treatment for Children and Adults Receives FDA Approval
Join the Global Movement Advancing Endocrine Science and Medicine
Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.